RT Journal Article
SR Electronic
T1 Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.01.02.24319734
DO 10.1101/2025.01.02.24319734
A1 Chandra, Jay
A1 Short, Sarah
A1 Rodriguez, Fatima
A1 Maron, David J.
A1 Pagidipati, Neha
A1 Hernandez, Adrian F.
A1 Mahaffey, Kenneth W.
A1 Shah, Svati H.
A1 Kiel, Douglas P.
A1 Lu, Michael T.
A1 Raghu, Vineet K.
A1 the Project Baseline Health Study Group
YR 2025
UL http://medrxiv.org/content/early/2025/01/02/2025.01.02.24319734.abstract
AB Chronological age is a cornerstone of medical decision-making but is limited because individuals age at different rates. We recently released an open-source deep learning model to assess biological age from chest radiograph images (CXR-Age), which predicts incident all-cause and cardiovascular mortality better than chronological age. Here, we compare CXR-Age to two established epigenetic aging clocks (First generation – Horvath Age; Second generation - DNAm PhenoAge), to test which is more strongly associated with measures of cardiopulmonary disease. Our cohort consisted of 2,097 participants from the Project Baseline Health Study (PBHS), a prospective cohort study of individuals from four US sites enriched for cardiovascular and cardiometabolic disease risk factors. We found that CXR-Age was most strongly associated with the presence of coronary calcium, cardiovascular risk factors, worsening pulmonary function, increased frailty, and abundance in plasma of two proteins implicated in neuroinflammation and aging. Associations with second generation epigenetic clocks were weaker for pulmonary function and for all outcomes in younger adults. No associations were found with first generation clocks. These results suggest that opportunistic screening using CXR-Age may help identify high risk individuals who could benefit from directed screening and prevention.Competing Interest StatementAll authors acknowledge institutional research grants from Verily Life Sciences. SS reports employment and equity ownership in Verily Life Sciences. KM reports grants from Verily, Afferent, the American Heart Association (AHA), Cardiva Medical Inc, Gilead, Luitpold, Medtronic, Merck, Eidos, Ferring, Apple Inc, Sanifit, and St. Jude; grants and personal fees from Amgen, AstraZeneca, Bayer, CSL Behring, Johnson & Johnson, Novartis, and Sanofi; and personal fees from Anthos, Applied Therapeutics, Elsevier, Inova, Intermountain Health, Medscape, Mount Sinai, Mundi Pharma, Myokardia, Novo Nordisk, Otsuka, Portola, SmartMedics, and Theravance outside the submitted work. AH reports grants from Verily; grants and personal fees from AstraZeneca, Amgen, Bayer, Merck, and Novartis; and personal fees from Boston Scientific outside the submitted work. VKR reports grants from the National Academy of Medicine, Norn Group, the American Heart Association, and the NHLBI and has common stock in Alphabet, Apple, NVIDIA, and Meta. MTL reports grants from the National Academy of Medicine, American Heart Association, AstraZeneca, Ionis, Johnson & Johnson Innovation, Kowa, Medimmune, NHLBI, and the Risk Management Foundation of the Harvard Medical Institutions Inc outside the submitted work.Funding StatementThe Baseline Health Study and this analysis were funded by Verily Life Sciences, South San Francisco, California.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mass General Brigham institutional review board with a waiver of informed consent for retrospective analysis of deidentified data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data used in the present study may be available with prior approval from Project Baseline Health Study